Altimmune Names Greg Weaver As Chief Financial Officer To Strengthen Financial Strategy

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced today that it has nominated Greg Weaver as its Chief Financial Officer. Weaver will be responsible for the company's financial issues, SEC reporting, and investor relations in this role.

“We are pleased to welcome Greg to Altimmune’s executive team during such a pivotal time in our evolution. He has a wealth of experience that we believe will be invaluable as we enter a crucial period in developing our lead program, pemvidutide, and our advancement as an organisation. We look forward to his contributions and are excited to leverage his expertise and broad industry relationships as we continue working to build value through the advancement of pemvidutide,” said Vipin K. Garg, PhD, President and Chief Executive Officer of Altimmune. 

Weaver brings rich experience, with more than 25 years in finance and prominently in life sciences. He was the most recent CFO at Cognito Therapeutics, a company in the clinical stage focused on neurodegenerative diseases. Before that, he was the CFO at Atai Life Sciences, which completed a $225 million Initial public offering in 2021. Weaver has had a career running capital market activity, product launches, and mergers and acquisitions for several biotech companies.

Mr Greg Weaver commented, “Pemvidutide is a unique and up-and-coming product candidate with broad therapeutic potential spanning a variety of metabolic disorders for which its direct liver targeting mechanism and robust lipid-lowering capabilities can be beneficial. The data generated to date in obesity and liver disease are extremely encouraging. With multiple significant milestones on the horizon, I am excited to play a role in Altimmune’s future success.”

In earlier stages of his career, Weaver held the position of CFO for publicly traded biotech companies, including Sirna Therapeutics, acquired by Merck, and ILEX Oncology, acquired by Genzyme. He is also currently a Director and the Chair of the Audit Committee for BioIntelliSense, a patient monitoring technology company, and Centenara Labs, a biopharma company centered around aging science. He is a director for HarborPath, a non-profit firm focused on access to medicines for life's essentials. Weaver is a U.S. Air Force veteran who has a B.A. degree in accounting and finance from Trinity University and an MBA from Boston College.